| Name | Title | Contact Details |
|---|
GW was co-founded in 1998 by Dr. Geoffrey Guy and Dr. Brian Whittle, two well-known entrepreneurs in the UK biotech sector. In setting up GW, Drs. Guy and Whittle worked closely with both the UK Home Office and the UK`s medicines regulatory authority on establishing necessary licences and procedures so as to facilitate the progress of GW`s cannabinoid research program.
Imaging Endpoints (IE) is an imaging research and core laboratory that provides imaging CRO services to evaluate drug and device efficacy. We specialize in providing the industry`s leading radiology expertise and most advanced technologies through exquisite service. • LOCATIONS: Imaging Endpoints is based in Scottsdale, AZ, with offices in Waltham, MA, and Hyderabad, India as well as new offices opening soon in Basel, Switzerland; Amsterdam, the Netherlands and Shanghai, China. • AFFILIATES: We are an affiliate of HonorHealth, one of the largest healthcare systems nationally. We are also an affiliate of Scottsdale Medical Imaging, Ltd., part of the largest private radiology group in the US. • DEEP SCIENCE: Our Medical and Scientific Affairs Team includes world-class leaders in imaging science. Over 50 publications in leading journals have established us as a technology leader. IE`s experience spans hundreds of successful studies across all phases of development, including the most complex and high-profile Phase 3 trials in the industry. • EXPERT READERS: Our team includes over 100 physician readers comprised of 40 in-house radiologists and academically based expert radiologists, oncologists, surgeons and other physicians in the US. • GLOBAL SERVICES: We are one of the largest global imaging CROs in oncology. We receive/read scans in real-time from hundreds of imaging sites in over 35 countries. • SETTING NEW QUALITY STANDARDS: Our imaging Quality Management System (iQMS) is designed to exceed industry standards. All inspections by FDA and EMEA have resulted in zero observations, clearly demonstrating our leadership in quality. • EXCEPTIONAL STABILITY: IE has experienced a decade of high growth with no ownership change or executive leadership change in over five years.
Corepharma LLC is one of the leading companies in the Healthcare, Pharmaceuticals, & Biotech sector.
Chugai Pharma USA (CPUSA), a wholly owned subsidiary of Chugai Pharmaceutical Co., Ltd.(Chugai) located in Berkeley Heights NJ, is focused on early stage clinical research, mainly in the disease areas of oncology, renal disease, and bone and joint disease. CPUSA operates as part of Chugai`s Translational Clinical Research Division (TCRD), a global function with offices in Europe, Japan and the U.S. TCRD is dedicated to late pre-clinical and early clinical development of Chugai-originated pipeline products. TCRD aims to accelerate the proof-of-concept process by bringing translational research-powered medicines to global development stage and ultimately to market, as efficiently as possible. Chugai`s specific focus is placed on bringing innovative therapies to market for conditions where treatment options may be limited and patient needs may be unmet. Chugai works in strategic alliance with Roche to pursue cutting-edge biopharmaceutical, antibody, and molecular-targeted research technologies-areas that constitute Chugai`s greatest strengths-as well as chemical synthesis technology. Chugai has achieved success with its original products and will continue to seek to provide exceptional value to patients. As a most important member of the Roche group, Chugai aims to become a top pharmaceutical company by providing a continuous flow of innovative new medicines internationally. CPUSA believes in success through collaboration, and our culture encourages innovation through sharing ideas. If being on the cutting edge of translational clinical research and development appeals to you, consider a career with CPUSA.
Inhaled nitric oxide has the potential to benefit patients, with a range of cardiopulmonary conditions including COVID-19 Coronavirus.